Procept BioRobotics Corp. is preparing to launch its AquaBeam Aquablation robot-controlled waterjet prostate resection device at the American Urological Association conference in San Francisco in May, touting it as a technology that will "fundamentally transform" the treatment of benign prostate hyperplasia (BPH).
About nine years after the Silicon Valley company was founded to develop the Aquablation technology, US FDA cleared AquaBeam via the de novo pathway on Dec